Physician profile
Rami Abbass
NPI 1659523405
$10,068.18
in general payments reported to CMS, 2019-2025
26 companies · $1,869 in 2025
The $1,869 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,008 · 2020: $594 · 2021: $1,132 · 2022: $1,199 · 2023: $1,523 · 2024: $1,742 · 2025: $1,869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,991 · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,990.56 |
| Education | $143.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,530.53 | 2019-2025 | Rinvoq, Skyrizi, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,431.70 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $1,039.11 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $971.00 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $887.49 | 2019-2025 | |
| Ardelyx, INC. | $559.58 | 2022-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $248.99 | 2023-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $238.69 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $216.17 | 2019-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $149.79 | 2022-2025 | Dupixent |
| Celgene Corporation | $140.58 | 2022-2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $116.92 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $62.02 | 2019-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $61.16 | 2024-2025 | Voquezna |
| Genzyme Corporation | $57.20 | 2022-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $56.20 | 2025 | Omvoh |
| Sandoz INC. | $54.13 | 2023-2024 | Hyrimoz |
| Qol Medical, LLC | $47.35 | 2021-2024 | Sucraid |
| Braintree Laboratories, INC. | $45.71 | 2019-2023 | Sutab |
| Celltrion USA INC. | $34.44 | 2025 | Vegzelma |
| Redhill Biopharma INC. | $33.68 | 2020-2022 | |
| Novo Nordisk INC | $30.58 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $18.66 | 2025 | Iqirvo |
| Allergan, INC. | $13.73 | 2019 | |
| Shire North American Group INC | $13.23 | 2019 | |
| Romark Laboratories, Lc | $9.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rami Abbass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.